搜索结果

   GABBR1

靶点ID:TCMBANKGE012171

靶点别名:GABABR1; GABBR1-3; GB1; GPRC3A

靶点描述:gamma-aminobutyric acid type B receptor subunit 1

染色体:6

染色体位置:6p22.1

靶点类型:protein-coding

HERB_ID:-

HGNC_Link:4070

OMIM_Link:603540

Ensembl_Link:ENSG00000204681

   靶点对应的植物
ID 拉丁名 药名 药用植物名 功能与主治 来源 药用部位 使用民族
   靶点对应的化合物
化合物ID 化合物名 别名 分子式 分子质量 Smiles
TCMBANKIN008919 isoguvacine MLS000859962; Isoguvacine hydrochloride, solid; I02-4338; SR-01000075611-3; 1,2,3,6-tetrahydro-4-pyridinecarboxylicacidhydrochloride; Lopac-G-002; G-002; SY012592; KBio1_000115; SMR000326821; 1,2,3,6-tetrahydropyridine-4-carboxylic acid; IDI1_000115; NCGC00093946-02; 1,2,3,6-Tetrahydro-pyridine-4-carboxylic acid hydrochloride; Tocris-0235; EU-0100561; Isoguvacine (hydrochloride); ISOGUVACINE HYDROCHLORIDE; NINDS_000115; 68547-97-7; SUWREQRNTXCCBL-UHFFFAOYSA-N; HY-100810; NCGC00024509-03; NCGC00093946-03; NCGC00015456-01; SCHEMBL7958625; TRA0081918; B6230; 1,2,3,6-Tetrahydro-4-pyridinecarboxylic acid hydrochloride; MFCD00055192; NCGC00024509-01; TR-022104; SPECTRUM1502129; Biomol-NT_000254; Isoguvacine; LP00561; SR-01000075611; KBio3_002820; FT-0670465; I0871; Spectrum_001974; SC-49605; C13694; AX8223448; 4-Pyridinecarboxylic acid, 1,2,3,6-tetrahydro-, hydrochloride; AKOS025243370; BPBio1_000882; 1,2,3,6-Tetrahydro-pyridine-4-carboxylic acid hydr; KBio2_007667; 4-Pyridinecarboxylic acid, 1,2,3,6-tetrahydro-; KS-00000AIF; MolPort-003-983-601; CCG-221865; BSPBio_003318; 1,2,3,6-Tetrahydro-4-pyridinecarboxylic acid; Lopac0_000561; AKOS015847455; NCGC00093946-01; 64603-90-3 (Parent); AK154352; 1,2,3,6-TETRAHYDRO-4-PYRIDINECARBOXYLIC ACID HCL; 1,2,3,6-Tetrahydro-pyridine-4-carboxylic acidhydrochloride; Tox21_500561; BN0277; KBio2_002531; SC-49604; AC1L4DMR; 1,2,3,6-tetrahydropyridine-4-carboxylic acid hydrochloride; CS-6967; SR-01000075611-1; DTXSID00218663; 1,2,5,6,-Tetrahydroisonicotinic acid Hydrochloride; KBioSS_002540; KBio2_005099; CHEMBL540303; Spectrum3_001869; Z-2044; NCGC00261246-01; DivK1c_000115; Isoguvacine HCl; 1,2,5,6-tetrahydroisonicotinic acid hydrochloride C6H9NO2 127.14 C1CNCC=C1C(=O)O
TCMBANKIN015528 levodopa Dopaston SE; Helfo-dopa; Eurodopa; Dopastral; Veldopa; Biodopa; Dopal; BSPBio_000053; Levedopa; SPBio_000391; L-O-Hydroxytyrosine; .Beta.-(3,4-Dihydroxyphenyl)-L-alanine; SPECTRUM2300205; Spectrum2_000496; beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine; KBio2_000934; 3,4-Dihydroxyphenylalanine (VAN); Cidandopa; (-)-Dopa; Pardopa; Levodopa (JP15/USP/INN); (2S)-2-amino-3-(3,4-dihydroxyphenyl)propionic acid; D9628; Dihydroxy-L-phenylalanine; (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid; Alanine, 3-(3, 4-dihydroxyphenyl)-, (-)-; Levodopum [INN-Latin]; DivK1c_000452; (-)-(3,4-Dihydroxyphenyl)alanine; L-(3, 4-Dihydroxyphenyl)-.alpha.-alanine; Prestwick3_000017; Brocadopa; L(-)-Dopa; EINECS 200-445-2; SDCCGMLS-0066924.P001; 3,4-Dihydroxyphenylalanine; Levopa; Dopar (TN); Dopal-fher; PDSP1_001541; Spectrum5_001899; L-(o-Dihydroxyphenyl)alanine; BPBio1_000059; Dopaflex; NSC118381; CHEBI:15765; nchembio.2007.55-comp26; 72572-99-7; Syndopa; Eldopatec; Lopac-D-9628; Alanine, 3-(3,4-dihydroxyphenyl)-, (-)-; Ro 4-6316; KBio2_006070; DAH; .Beta.-(3, 4-Dihydroxyphenyl)alanine; Dopalina; Doparl; KBioGR_001177; 3-Hydroxytyrosine; Lopac0_000454; InChI=1/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14; KBioSS_000934; Cerepar; Dopaston; L-Dihydroxyphenylalanine; L-3-Hydroxytyrosine; L-O-Dihydroxyphenylalanine; AIDS126624; beta-(3,4-dihydroxyphenyl)alanine; Prestwick1_000017; Helfo DOPA; AIDS-126624; Dopasol; L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine; beta-(3,4-Dihydroxyphenyl)-alpha-alanine; Alanine, 3-(3,4-dihydroxyphenyl)-; Tyrosine, 3-hydroxy-; NINDS_000452; NCGC00016270-01; Eldopar; Insulamina; NCGC00015384-01; D9628_SIGMA; Prodopa; PDSP2_001525; Dopaidan; Dopar; C00355; L-(-)-Dopa; KBio1_000452; Bendopa; Spectrum4_000539; D00059; 3,4-Dihydroxyphenyl-L-alanine; L-3-(3,4-Dihydroxyphenyl)alanine; CAS-59-92-7; CCRIS 3766; L-beta-(3,4-Dihydroxyphenyl)alanine; 23734-74-9; Levodopa; L-(3, 4-Dihydroxyphenyl)alanine; Sobiodopa; EU-0100454; Larodopa; Levodopa [USAN:BAN:INN:JAN]; L-.Beta.-(3,4-Dihydroxyphenyl)alanine; L Dopa; IDI1_000452; 88250-23-1; Doprin; Spectrum_000454; Component of Sinemet; 37830_FLUKA; Cerepap; Prestwick0_000017; 2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid; ST5330614; 25525-15-9; Prestwick_185; L-Tyrosine, 3-hydroxy-; 34241-25-3; 3, 4-Dihydroxy-L-phenylalanine; 72573-00-3; 90638-38-3; Doparkine; Prestwick2_000017; Eldopal; beta-(3,4-Dihydroxyphenyl)-L-alanine; MLS000028514; 3-Hydroxy-L-tyrosine; (-)-3-(3,4-Dihydroxyphenyl)-L-alanine; BSPBio_002354; SMR000058312; 3-(3,4-Dihydroxyphenyl)-L-alanine; SPBio_001974; HSDB 3348; NSC 118381; 587-45-1; Maipedopa; 3, 4-Dihydroxyphenylalanine; KBio2_003502; Deadopa C9H11NO4 197.19 C1=CC(=C(C=C1CC(C(=O)O)N)O)O
TCMBANKIN027412 scropolioside D C34H42O17 722.69 CC1C(C(C(C(O1)OC2C3C=COC(C3C4(C2O4)CO)OC5C(C(C(C(O5)CO)O)O)O)OC(=O)C)OC(=O)C=CC6=CC=CC=C6)OC(=O)C
TCMBANKIN032329 securinine securinine C13H15NO2 217.26 C1CCN2C(C1)C34CC2C=CC3=CC(=O)O4
TCMBANKIN038293 progesterone Cyclogesterin; Luteovis; Progeffik; (8S,9S,10R,13S,14S,17S)-17-ethanoyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; Gesterol 50; Corlutin; Syngestrets; NCGC00090798-02; D4-Pregnene-3,20-dione; Hormoluton; Pranone; Crinone progesterone gel; Gesterol 100; Prometrium; Proluton; Luteodyn; Prestwick0_000477; Progestasert; SPBio_002553; .delta.4-Pregnene-3,20-dione; Pregnenedione; NSC-9704; P3972_SIGMA; Methylpregnone; 4-Pregnene-3,20-dione; Prolutone; U 3672; Lutocylin; Colprosterone; Utrogest; Lutocylol; CHEBI:17026; SMR000058345; Corporin; Lipolutin; NCGC00090798-01; P8783_SIGMA; Synovex S; ACon1_002078; 3,20-Pregnene-4; Prestwick_411; Progesterone, water-soluble; Cyclogest; progesterone ; Luteal hormone; Prolets; AIDS070516; NCI60_042166; (S)-Pregn-4-en-3,20-dione; 6.alpha.-Methylpregn-4-en-17.alpha.-ol-3,20-dione; Prolidon; NSC 64377; (8S,9S,10R,13S,14S,17S)-17-Acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; Nalutron; Progesterone [BAN:INN:JAN]; Progesteronum [INN-Latin]; STR; Flavolutan; Percutacrine Luteinique; Prontogest; Lutocyclin M; Akrolutin; Lugesteron; Corlutina; SCHEMBL12237373; ZINC03814383; Gynlutin; Gynoluton; Prestwick3_000477; Lutogyl; Progesterone: 2-hydroxypropyl-beta-cyclodextrin complex; Crinone (TN); Gynolutone; Spectrum5_002053; Gesterol; AIDS-070516; Progestronol; Luteopur; Corpus luteum hormone; Lutoform; Luteol; 6alpha-Methylpregn-4-en-17alpha-ol-3,20-dione; 17alpha-Progesterone; STOCK1N-52522; Progesterona [INN-Spanish]; Hormoflaveine; Pregn-4-ene-3,20-dione, 17alpha-hydroxy-6alpha-methyl-; Progesterone [Progestins]; Delta(4)-pregnene-3,20-dione; Progesterone: HBC complex; Delta4-Pregnene-3,20-dione; .beta.-Progesterone; Piaponon; Progestrel; Primolut; Gestone; Pregnene-3,20-dione; Syntolutan; NSC64377; MEGxm0_000472; Progesteron; Gelbkoerperhormon; Membrettes; Progestogel; Gestron; EU-0100895; MLS000028517; Prolutin; EINECS 200-350-6; Luteinique; 57-83-0; Progestron; P9776_SIGMA; NCGC00179853-01; Luteol (VAN); Utrogestan; Lutidon; Progesterol; Luteosan; Gestormone; Gestiron; Progesterone; Lutocuclin M; D00066; Endometrin; Lutin; Progestol; Fologenon; C00410; BG01605063; Lucorteum; 8023-13-0; AI3-51682; 8012-32-6; Luteogan; Agolutin; Progesterone (JP15/USP/INN); 17.alpha.-Hydroxy-6.alpha.-methylpregn-4-ene-3,20-dione; MLS000758277; Crinone; 17alpha-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione; Luteohormone; S00293; BPBio1_000676; 17.alpha.-Progesterone; Pregn-4-ene-3,20-dione, 17.alpha.-hydroxy-6.alpha.-methyl-; CMC_13406; NSC 9704; NCGC00022185-06; Luteocrin normale; Progestosol; Protormone; (S)-4-Pregnene-3,20-dione; P6149_SIGMA; Luteine; Lutren; P7556_ALDRICH; 257630-50-5; COL-1620; MolPort-001-740-063; SBB012538; delta(sup4)-Pregnene-3,20-dione; NSC9704; component of Cyclogesterin; Syngesterone; FE-999913; Bio-luton; Prestwick1_000477; NCGC00022185-07; nchembio.2007.53-comp14; Pregn-4-ene-3,20-dione; (1S,3BS,9AR,11AS)-1-ACETYL-9A,11A-DIMETHYL-1H,2H,3H,3AH,3BH,4H,5H,8H,9H,9BH,10H,11H-CYCLOPENTA[A]PHENANTHREN-7-ONE; 753497-20-0; CCRIS 533; Vitarrine; delta(sup 4)-Pregnene-3,20-dione; Progestone; Luteum; Lipo-Lutin; Progestin; Lutociclina; Progesteronum; WLN: L E5 B666 OV MUTJ A1 E1 FV1; Progekan; .delta.(sup4)-Pregnene-3,20-dione; 46665_RIEDEL; AKOS030503393; Projestaject; Lingusorbs; Lucorteum Sol; Lopac0_000895; Lutex; P0130_SIGMA; Prochieve; Corluvite; BSPBio_000614; BRD-A51738545-001-01-0; Prestwick2_000477; Luteostab; Progesterone; 4-Pregnene-3,20-dione; Lutocyclin; Glanducorpin; Prometrium (TN); HSDB 3389; Lutromone; (S)-Progesterone C21H30O2 314.46 CC(=O)C1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C
TCMBANKIN057964 Immune globulin from;gaba;γ-aminobutyricacid;aminobutyric acid γ-aminobutyric acid C4H9NO2 C(CC(=O)O)CN
TCMBANKIN058192 isoliquiritigenin HCC; KBio2_000625; SPBio_000949; Spectrum2_000875; 961-29-5; 2-PROPEN-1-ONE, 1-(2,4-DIHYDROXYPHENYL)-3-(4-HYDROXYPHENYL)-; SPECTRUM1504200; Chalcone, 2',4,4'-trihydroxy-; CHEMBL1395334; KBio3_002631; NCGC00015556-01; SDCCGMLS-0066751.P001; ST5309279; (2E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; KBio2_003193; InChI=1/C15H12O4/c16-11-4-1-10(2-5-11)3-8-14(18)13-7-6-12(17)9-15(13)19/h1-9,16-17,19H/b8-3; (E)-1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one; CMLD3_000056; BSPBio_003411; C08650; CCRIS 7676; 2',4,4'-Trihydroxychalcone; Lopac0_000681; 1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; I159_SIGMA; 1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one; Lopac-I-3766; CPD-3041; KBio1_001802; MEGxp0_001326; ZINC3869607; BRN 1914295; MLS000438943; SMR000112969; Acrylophenone, 2',4'-dihydroxy-3-(p-hydroxyphenyl)-; (2E)-1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one; ACon1_000047; GU 17; KBioGR_002232; DivK1c_006858; KBio2_005761; 1-08-00-00707 (Beilstein Handbook Reference); 4,2′,4′-Trihydroxychalcone; (E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; NCGC00090504-01; (Z)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; EU-0100681; Spectrum3_001656; AC1O7G44; 4,2',4'-Trihydroxychalcone; EINECS 237-316-5; I3766_SIGMA; AIDS035379; AIDS-035379; 13745-20-5; Spectrum5_000612; 2-propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)-, (2E)-; Spectrum_000145; KBioSS_000625; Isoliquiritigenin; Spectrum4_001756; 42'4'-trihydroxychalcone; 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)-, (E)-; NCGC00090504-03; SpecPlus_000762; 2',4',4-trihydroxychalcone C15H12O4 256.25 g/mol C1=CC(=CC=C1C=CC(=O)C2=C(C=C(C=C2)O)O)O
   靶点对应的疾病
疾病ID 疾病名 MeSH名 HPO名 UMLS名 疾病类型
TCMBANKDI000018 Digestive System Diseases; Neoplasms; Endocrine System Diseases Abnormality of the digestive system; Neoplasm Neoplastic Process disease
TCMBANKDI000023 Skin and Connective Tissue Diseases; Immune System Diseases Abnormality of the immune system Disease or Syndrome disease
TCMBANKDI000054 Nervous System Diseases; Mental Disorders Abnormality of the nervous system Disease or Syndrome disease
TCMBANKDI000166 - - Neoplastic Process disease
TCMBANKDI003117 Nervous System Diseases - Disease or Syndrome disease
TCMBANKDI003353 Pathological Conditions, Signs and Symptoms; Neoplasms - Neoplastic Process phenotype
TCMBANKDI007031 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases; Endocrine System Diseases; Hemic and Lymphatic Diseases; Cardiovascular Diseases - Disease or Syndrome disease
TCMBANKDI009278 Mental Disorders - Mental or Behavioral Dysfunction group
TCMBANKDI014716 Nervous System Diseases - Disease or Syndrome disease
TCMBANKDI015485 Mental Disorders Abnormality of the nervous system Mental or Behavioral Dysfunction disease
TCMBANKDI017008 Pathological Conditions, Signs and Symptoms; Nervous System Diseases Abnormality of the nervous system Disease or Syndrome disease
TCMBANKDI019267 Pathological Conditions, Signs and Symptoms; Nervous System Diseases Abnormality of the nervous system Sign or Symptom phenotype
TCMBANKDI019573 Chemically-Induced Disorders; Mental Disorders - Mental or Behavioral Dysfunction disease
TCMBANKDI020647 Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Chemically-Induced Disorders - Disease or Syndrome disease
TCMBANKDI022574 Chemically-Induced Disorders; Mental Disorders - Mental or Behavioral Dysfunction disease
TCMBANKDI023391 Mental Disorders - Mental or Behavioral Dysfunction group
TCMBANKDI023464 Nervous System Diseases Abnormality of the nervous system Disease or Syndrome disease
TCMBANKDI023498 Skin and Connective Tissue Diseases; Musculoskeletal Diseases - Disease or Syndrome disease
TCMBANKDI031189 Neoplasms Neoplasm; Abnormality of the respiratory system Neoplastic Process disease
TCMBANKDI032193 Behavior and Behavior Mechanisms Abnormality of the nervous system Mental or Behavioral Dysfunction phenotype

Home | Browse | Search | Predict | Data | Contact | Help

Copyright © KUST | 滇IICP备16009434号-1 | Dai SX Lab